From the President who made social media a key tool in his campaign comes the biggest news for health care, pharmaceuticals, biotech and medical device manufacturers yet: an articulated vision for health care reform that is gaining traction. What the final legislation will look like is anyone’s guess: Will it be, as The New England Journal of Medicine suggests a “value-based system”? Read more »

Warning letters. Off-label promotion. Adverse drug reaction reporting. These are compelling reasons why pharmaceutical, biotechnology and medical device marketers should be nervous about social media. Read more »

URCH reports in their newly available Cancer Market Trends 2008 – 2012 that Roche is expected to overtake Amgen as the top seller of oncology products. Only Genentech and Merck are expected to post double digit growth, causing a shift in balance for former leaders anofi-Aventis, AstraZeneca and Johnson & Johnson. Read more »